AAAAAA
Results:
1-7
|
Results: 7
Authors:
Marriott, JB
Muller, G
Stirling, D
Dalgleish, AG
Citation: Jb. Marriott et al., Immunotherapeutic and antitumour potential of thalidomide analogues, EXPERT OP B, 1(4), 2001, pp. 675-682
Authors:
Marriott, JB
Clarke, IA
Dalgleish, AG
Citation: Jb. Marriott et al., Inhibition of p38 MAP kinase during cellular activation results in IFN-gamma-dependent augmentation of IL-12 production by human monocytes/macrophages, CLIN EXP IM, 125(1), 2001, pp. 64-70
Authors:
La Maestra, L
Zaninoni, A
Marriott, JB
Lazzarin, A
Dalgleish, AG
Barcellini, W
Citation: L. La Maestra et al., The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro, CLIN EXP IM, 119(1), 2000, pp. 123-129
Authors:
Heriot, AG
Marriott, JB
Cookson, S
Kumar, D
Dalgleish, AG
Citation: Ag. Heriot et al., Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection, BR J CANC, 82(5), 2000, pp. 1009-1012
Authors:
Brown, L
Souberbielle, BE
Marriott, JB
Westby, M
Desselberger, U
Kaye, T
Gougeon, ML
Dalgleish, A
Citation: L. Brown et al., The conserved carboxy terminal region of HIV-1 gp120 is recognized by seronegative HIV-exposed people, AIDS, 13(18), 1999, pp. 2515-2521
Authors:
Marriott, JB
Muller, G
Dalgleish, AG
Citation: Jb. Marriott et al., Thalidomide as an emerging immunotherapeutic agent, IMMUNOL TOD, 20(12), 1999, pp. 538-540
Authors:
Dalgleish, AG
Marriott, JB
Souberbielle, B
Montesano, C
Sheikh, J
Sidebottom, D
Westby, M
Austen, B
Citation: Ag. Dalgleish et al., The role of HIV gp120 in the disruption of the immune system, IMMUNOL LET, 66(1-3), 1999, pp. 81-87
Risultati:
1-7
|